The Tropical Biopharmaca Research Center (TropBRC) IPB University served as the venue for the 2nd Focus Group Discussion (FGD) on BioLowTens, an antihypertensive herbal product, held on Thursday, 27 November 2025, at the IPB Taman Kencana Campus in Bogor. This activity is part of the pre–Feasibility Study within the 2025 Technology Push Hiliriset Program, which aims to refine the downstreaming strategy before the product enters the commercialization stage. The FGD was organized by the UNPAD Expert Team and involved the IPB inventor team, industry partners, and other key stakeholders.
During the first FGD, initial inputs were gathered regarding technical, marketing, financial, and regulatory aspects. The second meeting focused on verifying these findings, aligning downstreaming strategies, and identifying remaining issues that need further refinement prior to completing the final study report. This consolidation phase is essential to ensure that the BioLowTens development strategy is feasible, measurable, and sustainable.
The discussion covered a wide range of topics, including technology readiness, market segmentation, branding strategies, potential production partnerships with industry, and financial feasibility. Participants also reviewed legal and regulatory requirements for BioLowTens as it progresses toward production and market entry. Through this collaborative platform, each analytical component is expected to be strengthened, resulting in a comprehensive and strategic downstreaming roadmap.
The outcomes of this second FGD will serve as the basis for final recommendations and the completion of the comprehensive study report. This document will guide IPB University, UNPAD, and industry partners in progressing toward production, regulatory approval, and commercialization of BioLowTens. The collaboration formed through this activity reflects a shared commitment to advancing high-quality, safe, and competitive Indonesian herbal innovations.
As a closing note, the FGD underscores the importance of collaborative research development that delivers real benefits to society. May the downstreaming process of BioLowTens proceed smoothly and become an example of successful research translation into impactful health products for the nation. Keep moving forward—strengthening research, fostering innovation, and contributing to a healthier Indonesia.
